natgillin/translations-raw huggingface dataset:
Raltegravirf (400 mg to gange dagligt)
Raltegravirf (400 mg twice daily)
Raltegravirs farmakokinetik hos spædbørn under 4 uger er ikke fastlagt.
The pharmacokinetics of raltegravir in infants under 4 weeks of age has not been established.
Raltegravirs farmakokinetiske parametre IMPAACT P1066 efter administration af doser i pkt 4.2
Raltegravir Pharmacokinetic Parameters IMPAACT P1066 Following Administration of Doses in Section 4.2
Raltegravirs sikkerhed og virkning hos spædbørn under 4 uger er endnu ikke klarlagt.
Safety and efficacy of raltegravir in infants below 4 weeks of age have not yet been established.
Ralteravir elimineres primært ved glucuronidering i leveren.
Raltegravir is eliminated primarily by glucuronidation in the liver.
Ramucirumab er et humant, receptor-målrettet antistof, som specifikt binder sig til VEGF-receptor 2 og blokerer binding af VEGF-A, VEGF-C og VEGF-D.
Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D.
Ramucirumab er opbygget, så det binder sig til en receptor for proteinet VEGF (vaskulær endotelial vækstfaktor).
Ramucirumab has been designed to attach to a receptor for a protein called vascular endothelial growth factor (VEGF).
Ramucirumab i kombination med docetaxel
Ramucirumab in combination with docetaxel
Ramucirumab i kombination med paclitaxel
Ramucirumab in combination with paclitaxel
Ramucirumab skal anvendes med forsigtighed hos patienter med svær levercirrose (Child-Pugh B eller C), cirrose med hepatisk encephalopati, klinisk signifikant ascites forårsaget af cirrose eller hepetorenalt syndrom.
Ramucirumab should be used with caution in patients with severe liver cirrhosis (Child-Pugh B or C), cirrhosis with hepatic encephalopathy, clinically significant ascites due to cirrhosis, or hepatorenal syndrome.
Ramucirumab som enkeltstof
Ramucirumab as a single agent
Randomiserede forsøgspersoner
Patients randomised
Randomiserede kontrollede data viste ikke en øget risiko for hjerte-karsygdomme hos kvinder, som har fået fjernet deres livmoder, og som kun tager østrogen.
Randomised controlled data found no increased risk of coronary artery disease in hysterectomised women using oestrogen-only therapy.
Randomiserede kontrollede data viste ikke enøget t risiko for koronar arteriesygdom hos hysterektomerede kvinder, der behandles med østrogen alene.
Randomised controlled data found no increased risk of CAD in hysterectomised women using oestrogen-only therapy.
Randomiserede og behandlede
Randomized and treated patients
Randomiserede og behandlede patienter
Randomised and treated patients
Randomiserede og behandlede patienter
Randomized and treated patients
Randomiserede og behandlede patienter med baseline-værdi og mindst 1 post-baseline-effektmåling.
Randomized and treated patients with baseline and at least 1 post-baseline efficacy measurement.
Randomiserede patienter
Subjects randomized
Randomiserede patienter fik enten "lavdosis"- UFH-regimet (50 E/kg uanset brug af planlagt GPIIb/IIIa; ikke ACT-vejledt) eller "standarddosis"- UFH-regimet (ingen brug af GPIIb/IIIa: 85 E/kg, ACT-vejledt; planlagt brug af GPIIb/IIIa: 60 E/kg, ACT-vejledt) umiddelbart inden påbegyndelse af PCI.
Randomised patients received either “low dose” UFH regimen (50 U/kg irrespective of planned GPIIb/IIIa use; non ACT guided) or “standard dose” UFH regimen (no GPIIb/IIIa use: 85 U/kg, ACT guided; planned GPIIb/IIIa use: 60 U/kg, ACT guided) immediately prior to the start of the PCI.
Randomiserede patienter med stadie III optimalt tumorreduceret sygdom 2,3
Randomised patients stage III optimally debulked disease 2,3
Randomiserede patienter med stadie IV-sygdom
Randomised patients with stage IV disease
Randomiserede patienter, N
Subjects randomized
Randomiserede, dobbeltblindede overkrydsningsforsøg med en enkelt og multiple doser med 204 raske frivillige viste, at Filgrastim HEXALs farmakokinetiske profil var sammenlignelig med referenceproduktets efter subkutan og intravenøs administration.
Randomised, double-blind, single and multiple dose, crossover studies in 204 healthy volunteers showed that the pharmacokinetic profile of Filgrastim HEXAL was comparable to that of the reference product after subcutaneous and intravenous administration.
Randomiserede, dobbeltblindede overkrydsningsforsøg med en enkelt og multiple doser med 204 raske frivillige viste, at Zarzios farmakokinetiske profil var sammenlignelig med referenceproduktets efter subkutan og intravenøs administration.
Randomised, double-blind, single and multiple dose, crossover studies in 204 healthy volunteers showed that the pharmacokinetic profile of Zarzio was comparable to that of the reference product after subcutaneous and intravenous administration.
Randomiseret
Randomised
Randomiseret
Randomized
Randomiseret behandling†
Randomised Treatment
Randomiseret fase 2-studie med nivolumab i kombination med ipilimumab og ipilimumab (CA209069) Studie CA209069 var et randomiseret, dobbeltblindt fase 2-studie, som sammenlignede kombinationen af nivolumab og ipilimumab med ipilimumab alene hos 142 patienter med fremskredent (inoperabelt eller metastatisk) melanom med lignende inklusionskriterier som i studie CA209067 og den primære analyse hos patienter med BRAF-vildtype-melanom (77% af patienterne).
Randomised phase 2 study of nivolumab in combination with ipilimumab and ipilimumab (CA209069) Study CA209069 was a randomised, Phase 2, double-blind study comparing the combination of nivolumab and ipilimumab with ipilimumab alone in 142 patients with advanced (unresectable or metastatic) melanoma with similar inclusion criteria to study CA209067 and the primary analysis in patients with BRAF wild-type melanoma (77% of patients).
Randomiseret kontrolleret studie
Randomized controlled trial
Randomiseret Liraglutid + metformin
Randomised Liraglutide + metformin
Randomiseret og behandlet
Randomized and treated
Randomiseret og behandlet patienter
Randomised and treated patients
Randomiseret og behandlet Patienter
Randomized and treated patients
Randomiseret population+
Randomized Population+
Randomiseret sammenligning af behandling, som indeholdt dosering med abacavir og lamivudin én gang daglig vs. dosering 2 gange daglig blev foretaget indenfor et randomiseret, multicenter, kontrolleret studie med hiv-inficerede pædiatriske patienter.
A randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients.
randomiseret til EBR + GZR
EBR* + GZR
Randomiseret, åben label forsøg med parallelle grupper blev gennemført for at undersøge FEV1- ændringer efter initiering af EXUBERA-behandling hos type 1 og type 2 diabetikere.
Randomised, open label parallel group studies were conducted to examine FEV1 changes following initiation of EXUBERA therapy in type 1 and 2 subjects.
Randomisering blev stratificeret efter PD-L1- ekspression (≥5% versus <5% tumorcellemembran-ekspression), BRAF-status og M-stadie ifølge American Joint Committee on Cancer (AJCC) stadieklassificering.
Randomisation was stratified by PD-L1 expression (≥5% vs. <5% tumour cell membrane expression), BRAF status, and M stage per the American Joint Committee on Cancer (AJCC) staging system.
Randomisering blev stratificeret i forhold til BRAF- og PD-L1-tumorstatus samt bedste respons på tidligere ipilimumab-behandling.
Randomisation was stratified by BRAF and tumour PD-L1 status and best response to prior ipilimumab.
Randomisering blev stratificeret med anvendelse af tenofovirdisoproxilfumarat og/eller lopinavir/ritonavir i baseline-programmet.
Randomisation was stratified by use of tenofovir disoproxil fumarate and/or lopinavir/ritonavir in the baseline regimen.
Randomisering blev stratificeret ved screening af hiv- RNA-koncentrationen (≤50.000 kopier/ml og 50.000 kopier/ml) og ved hepatitis B- eller C-status (positiv eller negativ).
Randomization was stratified by screening HIV RNA level (≤50,000 copies/ml; and > 50,000 copies/ml) and by hepatitis B or C status (positive or negative).
Randomisering blev stratificeret ved screening af hiv- RNA-koncentrationen (≤50.000 kopier/ml og >50.000 kopier/ml) og ved hepatitis B- eller C-status (positiv eller negativ).
Randomization was stratified by screening HIV RNA level (≤50,000 copies/ml; and > 50,000 copies/ml) and by hepatitis B or C status (positive or negative).
Randomisering til 12 måneder
Randomization to 12 months
Randomisering til 24 måneder
Randomization to 24 months
Randomisering til 30 måneder
Randomization to 30 months
Randomisering til 36 måneder
Randomization to 36 months
Randomiseringen blev stratificeret efter geografisk region (Europa, Nordamerika og andet), tidligere VEGF/VEGFR-målrettet behandling (patienter kan have fået 0 eller 1 tidligere VEGF/VEGFR- målrettet behandling) og alder (≤ 65 år eller > 65 år).
Randomisation was stratified by geographic region (Europe, North America, and Other), prior VEGF/VEGFR-targeted therapy (patients may have received 0 or 1 prior VEGF/VEGFR-targeted therapy), and age (≤65 years or >65 years).
Randomiseringen blev stratificeret efter PDGFR-α-ekspression (positiv versus negativ), antal tidligere behandlingslinjer (0 versus 1 eller flere linjer), histologisk tumortype (leiomyosarkom, synovialt sarkom og andre) og ECOG-performancestatus (0 eller 1 versus 2).
Randomisation was stratified by PDGFR-α expression (positive versus negative), number of previous lines of treatment (0 versus 1 or more lines), histological tumour type (leiomyosarcoma, synovial sarcoma, and others) and ECOG performance status (0 or 1 versus 2).
Randomiseringen var stratificeret efter geografisk region, køn, tidligere vedligeholdelsesbehandling og ECOG-PS.
Randomisation was stratified by geographic region, gender, prior maintenance, and ECOG PS.
Ranexa 375 mg depottabletter
Ranexa 375 mg prolonged-release tablets
Ranexa 375 mg depottabletter Ranolazin
Ranexa 375 mg prolonged-release tablets Ranolazine
Ranexa 500 mg depottabletter Ranolazin
Ranexa 500 mg prolonged-release tablets Ranolazine
Ranexa 500 mg-depottabletter
Ranexa 500 mg prolonged-release tablets
Ranexa 750 mg depottabletter Ranolazin
Ranexa 750 mg prolonged-release tablets Ranolazine
Ranexa 750 mg-depottabletter
Ranexa 750 mg prolonged-release tablets
Ranexa bør ikke anvendes hos patienter, der er i behandling med CYP3A4- induktorer, f.eks. rifampicin, phenytoin, phenobarbital, carbamazepin og prikbladet perikon (se pkt.
Ranexa should not be used in patients treated with CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine, St. John’s Wort) (see section 4.5).
Ranexa depottabletter er ovale.
Ranexa prolonged-release tablets are oval shaped tablets.
Ranexa er indiceret som supplement til symptomatisk behandling af stabil angina pectoris hos voksne patienter, der ikke er tilstrækkeligt kontrolleret, eller som ikke tåler førstevalgsbehandling (såsom betablokkere og/eller calciumantagonister).
Ranexa is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
Ranexa er kontraindiceret til patienter, der tager:
Ranexa is contraindicated in patients taking:
Ranexa fås som depottabletter med 375 mg, 500 mg og 750 mg.
Ranexa is available as 375 mg, 500 mg, and 750 mg prolonged-release tablets.
Ranexa kan have bivirkninger såsom svimmelhed (almindeligt), uklart syn (ikke almindeligt), forvirring (ikke almindeligt), hallucinationer (ikke almindeligt), dobbeltsyn (ikke almindeligt) eller koordinationsforstyrrelser (sjældent), som kan påvirke din evne til at køre eller betjene maskiner.
Ranexa may cause side effects such as dizziness (common), blurred vision (uncommon), confusional state (uncommon), hallucination (uncommon), double vision (uncommon), coordination problems (rare), that may affect your ability to drive or use machines.
Ranexa kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, this medicine can cause side effects, although not everybody gets them..
Ranexa kan tages med eller uden mad.
They may be taken with or without food.
Ranexa var mere effektivt end placebo til at øge den tid, patienterne kunne motionere i.
Ranexa was more effective than placebo at increasing the length of time the patients could exercise.
Ranexa var signifikant bedre end placebo til at forlænge arbejdsvarigheden, tid til angina-anfald og tid til 1 mm- ST-segment-depression ved alle undersøgte doser med et observeret dosis-respons-forhold.
Ranexa was significantly superior to placebo in prolonging exercise time, time to angina, and time to 1 mm ST segment depression at all doses studied with an observed dose-response relationship.
Ranexas udseende og pakningsstørrelse
What Ranexa looks like and contents of the pack
Ranexa® informationskort (Du skal altid have kortet på dig)
Ranexa® Patient Alert Card (Carry this card with you at all times)
Ranexa® informationskort (Information til læger og sundhedspersonale)
Ranexa Patient Alert Card (Information for Health Care Professionals)
Ranibizumab 0,5 mg Gruppe I ved stabilisering (n=105)
Ranibizumab 0.5 mg Group I by stabilisation (n=105)
Ranibizumab 0,5 mg Gruppe II ved sygdomsaktivitet (n=116)
Ranibizumab 0.5 mg Group II by disease activity (n=116)
Ranibizumab 0,5 mg/Verteporfin PDT Gruppe III fra måned 3 og frem (n=55)
Ranibizumab 0.5 mg/Verteporfin PDT Group III from Month 3 onwards (n=55)
Ranibizumab er udformet, så det blokerer et stof, der kaldes vaskulær endotelial vækstfaktor A (VEGF- A).
Ranibizumab has been designed to block a substance called vascular endothelial growth factor A (VEGF-A).
Ranibizumab tilladt
Ranibizumab allowed
Ranibizumabs sikkerhed og virkning hos børn er endnu ikke klarlagt.
The safety and efficacy of ranibizumab have not yet been studied in paediatric patients.
Ranitidin (saquinavir/ritonavir)
Corticosteroids
Ranitidin / abacavir
Ranitidine/Abacavir
Ranitidin: Samtidig indtagelse af ranitidin og Pradaxa havde ingen klinisk relevant virkning på omfanget af dabigatran-absorptionen.
Ranitidine: Ranitidine administration together with Pradaxa had no clinically relevant effect on the extent of absorption of dabigatran.
Rapaglinids farmakokinetik er karakteriseret af et lavt fordelingsvolumen på 30 liter (svarende til fordeling i intracellulær-væsken) og er stærkt bundet til plasma proteiner i mennesker (mere end 98%).
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than 98%).
Rapaglinids farmakokinetik er karakteriseret af et lavt fordelingsvolumen på 30 liter (svarende til fordeling i intracellulær-væsken) og er stærkt bundet til plasma proteiner i mennesker (mere end 98%).
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid), and is highly bound to plasma proteins in humans (greater than 98%).
Rapamune 0,5 mg leveres som beige, trekantformede, overtrukne tabletter mærket ”RAPAMUNE 0.5 mg” på den ene side.
Rapamune 0.5 mg is supplied to you as tan-coloured, triangular-shaped coated tablets marked “RAPAMUNE 0.5 mg” on one side.
Rapamune 0,5 mg overtrukne tabletter Rapamune 1 mg overtrukne tabletter Rapamune 2 mg overtrukne tabletter Sirolimus
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets Sirolimus
Rapamune 0,5 mg overtrukne tabletter Sirolimus
Rapamune 0.5 mg coated tablets Sirolimus
Rapamune 0,5 mg tabletter Sirolimus
Rapamune 0.5 mg tablets Sirolimus
Rapamune 1 mg leveres som hvide, trekantformede, overtrukne tabletter mærket ”RAPAMUNE 1 mg” på den ene side.
Rapamune 1 mg is supplied to you as white-coloured, triangular-shaped coated tablets marked “RAPAMUNE 1 mg” on one side.
Rapamune 1 mg overtrukne tabletter Sirolimus
Rapamune 1 mg coated tablets Sirolimus
Rapamune 1 mg tabletter Sirolimus
Rapamune 1 mg tablets Sirolimus
Rapamune 1 mg/ml oral opløsning
Rapamune 1 mg/mL oral solution
Rapamune 1 mg/ml oral opløsning Sirolimus
Rapamune 1 mg/mL oral solution Sirolimus
Rapamune 1 mg/ml, oral opløsning
Rapamune 1 mg/mL oral solution
Rapamune 2 mg leveres som gul-beige, trekantformede, overtrukne tabletter mærket ”RAPAMUNE 2 mg” på den ene side.
Rapamune 2 mg is supplied to you as yellow to beige-coloured, triangular-shaped coated tablets marked “RAPAMUNE 2 mg” on one side.
Rapamune 2 mg overtrukne tabletter
Rapamune 2 mg coated tablets.
Rapamune 2 mg overtrukne tabletter Sirolimus
Rapamune 2 mg coated tablets Sirolimus
Rapamune 2 mg tabletter Sirolimus
Rapamune 2 mg tablets Sirolimus
Rapamune anvendes til at forebygge, at kroppen afstøder en nytransplanteret nyre.
Rapamune is used to prevent the body from rejecting a newly transplanted kidney.
Rapamune blev vurderet i et kontrolleret klinisk forsøg af 36 måneders varighed, hvor der er inklude- ret nyretransplanterede patienter i alderen under 18 år, som anses for at have en høj immunologisk risiko, defineret som havende én eller flere akutte episoder med afstødning af homologt transplantat i anamnesen og/eller med tilstedeværelse af kronisk afstødning af nyretransplantat bekræftet ved nyre- biopsi.
Rapamune was assessed in a 36-month controlled clinical study enrolling renal transplant patients below 18 years of age considered at high-immunologic risk, defined as having a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy.
Rapamune blev vurderet i et kontrolleret klinisk forsøg af 36 måneders varighed, hvor der er inklude- ret nyretransplanterede patienter i alderen under 18 år, som anses for at have en høj immunologisk risiko, defineret som havende én eller flere akutte episoder med afstødning af homologt transplantat i anamnesen og/eller med tilstedeværelse af kronisk afstødning af nyretransplantat bekræftet ved nyrebiopsi.
Rapamune was assessed in a 36-month controlled clinical study enrolling renal transplant patients below 18 years of age considered at high-immunologic risk, defined as having a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy.
Rapamune bør initialt anvendes sammen med ciclosporin mikro- emulsion og kortikosteroider i 2-3 måneder.
It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months.
Rapamune bør kun anvendes på tvingende indikation til gravide.
Rapamune should not be used during pregnancy unless clearly necessary.
Rapamune er blevet undersøgt i to hovedundersøgelser med i alt 1 295 patienter, der skulle have en nyretransplantation, og som havde lav til moderat risiko for organafstødning.
Rapamune has been studied in two main studies involving a total of 1,295 patients who were having a kidney transplant and were at low to moderate risk of rejection.
Rapamune er et lægemiddel, der indeholder det aktive stof sirolimus.
Rapamune is a medicine that contains the active substance sirolimus.
Rapamune er udelukkende til indtagelse gennem munden.
Rapamune is for oral use only.
Rapamune gives som en indledende dosis på 6 mg så hurtigt som muligt efter transplantationen, efterfulgt af 2 mg en gang dagligt i to til tre måneder.
Rapamune is given as an initial dose of 6 mg as soon as possible after the transplant, followed by 2 mg once a day for two to three months.
Rapamune indeholder op til 2,5 vol % ethanol (alkohol).
Rapamune contains up to 2.5 vol % ethanol (alcohol).
Rapamune kan, som al anden immunhæmmende medicin, nedsætte kroppens evne til at bekæmpe infektioner og kan øge risikoen for kræft i lymfevæv og hud.
Rapamune, like other immunosuppressive medicines, may decrease your body’s ability to fight infection, and may increase the risk of developing cancer of the lymphoid tissues and skin.
Rapamune nedsætter kroppens egne forsvarsmekanismer og forhindrer, at det transplanterede organ afstødes.
Rapamune reduces your body’s own defence mechanisms to stop rejecting your transplanted organ.
Rapamune nedsætter kroppens egne forsvarsmekanismer og forhindrer, at det transplanterede organ afstødes.
Rapamune reduces your body’s own defence mechanisms to stop you rejecting your transplanted organ.
Rapamune oral opløsning er en lysegul til gul opløsning, som leveres i en 60 ml flaske.
Rapamune oral solution is a pale yellow to yellow solution supplied in a 60 mL bottle.
Rapamune oral opløsning indeholder op til 2,5 vol % ethanol (alkohol).
Rapamune oral solution contains up to 2.5 vol % ethanol (alcohol).
Rapamune oral opløsning indeholder polysorbat-80, som er kendt for at øge hastigheden af di-(2- ethylhexyl)phthalat-ekstraktionen fra polyvinylchlorid (PVC).
Rapamune oral solution contains polysorbate-80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC).
Rapamune skal tages konsekvent enten med eller uden mad.
Rapamune should be taken consistently, either with or without food.
Rapamune var mere effektivt end placebo eller azathioprin, når de blev givet som tillægsbehandling til ciclosporin og kortikosteroider.
Rapamune was more effective than placebo or azathioprine, when they were added to ciclosporin and corticosteroids.
Rapamune-behandlingen bør optimeres med gradvist aftagende behandling med steroid- er og ciclosporin mikroemulsion.
Rapamune therapy should be optimised with a tapering regimen of steroids and ciclosporin microemulsion.
Rapamunes sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of Rapamune in children and adolescents less than 18 years of age have not been established.
Rapilysin 10 E pulver og solvens til injektionsvæske, opløsning
Rapilysin 10 U powder and solvent for solution for injection
Rapilysin 10 E pulver og solvens til injektionsvæske, opløsning reteplase
Rapilysin 10 U powder and solvent for solution for injection reteplase
Rapilysin bør injiceres gennem en i.v. adgang, som kun anvendes til injektion af Rapilysin.
Rapilysin should be injected preferably through an intravenous line that is used only for the injection of Rapilysin.
Rapilysin EMA/55700/2016
Rapilysin
Rapiscan 400 mikrogram injektionsvæske, opløsning Regadenoson
Rapiscan 400 microgram solution for injection Regadenoson
Rapiscan anvendes hos patienter, der ikke er i stand til at motionere nok til skanningen.
It is used in patients who are unable to exercise enough for the scan
Rapiscan anvendes som et ‘stress-stof’, der har en tilsvarende virkning på hjertet som motion.
Rapiscan is used as a ‘stress agent’ that has a similar effect on the heart as exercise.
Rapiscan anvendes til en form for hjerteskanning hos voksne, som hedder ‘radionuklear undersøgelse af myokardieperfusionen (myokardieskintigrafi)’.
Rapiscan is used in a type of heart scan in adults called ‘myocardial perfusion imaging’.
Rapiscan bør bruges med forsigtighed til patienter med tidligere atrieflimren eller atrieflagren.
Rapiscan should be used with caution in patients with a history of atrial fibrillation or flutter.
Rapiscan bør ikke anvendes til børn og unge under 18 år.
Rapiscan should not be used in children and adolescents below the age of 18 years.
Rapiscan bør ikke anvendes under graviditeten, medmindre det er klart nødvendigt.
Rapiscan should not be used during pregnancy unless clearly necessary.
Rapiscan er en selektiv koronar vasodilatator til opnåelse af farmakologisk stress ved radionuklear undersøgelse af myokardieperfusionen (myokardieskintigrafi) hos voksne patienter, som ikke kan opnå tilstrækkelig fysisk stressbelastning.
Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Rapiscan indgives som en intravenøs injektion.
Rapiscan is administered by intravenous injection.